Last updated: February 25, 2026
What is the Drug Identified by NDC 54092-0546?
The National Drug Code (NDC) 54092-0546 identifies Vyondys 53 (golodirsen), a prescription medication approved by the FDA in December 2019. It is used to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed genetic mutation amenable to exon 53 skipping.
Market Size and Patient Population
Patient Demographics
- Estimated patients with DMD in the U.S. with exon 53 skipping mutation: approximately 2,000-3,000.
- DMD affects approximately 1 in 5,000 live male births.
- The subset eligible for Vyondys 53: about 20-25% of DMD patients, due to mutation-specific targeting.
Market Penetration
- Initial adoption rates are gradual; from launch until 2022, market penetration reached roughly 15%, driven by specialist availability.
- Expected growth rate: 7% annually over the next five years as awareness and diagnosis improve.
Competitive Landscape
- Competing products include Emflaza (deflazacort), a corticosteroid, and Viltepso (viltolarsen), another exon-skipping drug targeting exon 53.
- Vyondys 53's unique position is due to its mutation-specific efficacy and FDA approval for exon 53 mutations.
Price History and Current Pricing
Launch Price
- Launched at approximately $300,000 per year for treatment.
Price Trends
- Prices remained stable post-launch, with minor adjustments for inflation and manufacturing costs.
- Reimbursement challenges limit patient access, subtly impacting revenue projections.
Price Comparison
| Product |
Year of Approval |
Annual Cost |
Indication |
| Vyondys 53 |
2019 |
$300,000 |
DMD with exon 53 skipping mutation |
| Viltepso |
2020 |
$300,000 |
Similar exon 53 skipping indication |
| Emflaza |
2017 |
$89,000 |
DMD (broader indication) |
(All prices approximate and subject to negotiation)
Revenue Projections
Short-term Outlook (2023-2025)
- Sales volume: projected to reach 400-600 patients annually.
- Revenue: estimated between $120 million and $180 million annually, assuming steady 15-20% market share.
Long-term Outlook (2026-2030)
- Market penetration expected to increase by 5-10% annually with increased diagnosis.
- Revenue could reach $250 million to $400 million by 2030 if broader access occurs.
Key Factors Influencing Revenue:
- Off-label use constraints.
- Insurance coverage and reimbursement rates.
- Competitive pressures from emerging exon skips and gene therapies.
Cost and Reimbursement Policies
- Price reimbursement varies by payer, with manufacturer negotiations impacting net pricing.
- Recent legislation pressures to lower drug prices may lead to discounts, affecting margins.
- Access disparities fall along payer types, with private insurers more likely to cover than Medicaid or uninsured.
Future Market Drivers
- Diagnostics improvement: Enhanced genetic screening increases eligible patient detection.
- Pipeline developments: New exon-skipping agents or gene editing therapies promise competition.
- Regulatory changes: Orphan drug status secures market exclusivity until 2025, after which biosimilars could enter.
Key Takeaways
- NDC 54092-0546 corresponds to Vyondys 53, targeting a mutation-specific subset of DMD.
- The current market size is approximately 2,000-3,000 patients in the U.S.
- Launch prices remain high at ~$300,000 per year; stable but under pressure.
- Short-term revenue is projected between $120-$180 million; long-term growth depends on diagnosis rates and reimbursement policies.
- Competition for exon 53 skipping drugs is increasing, with pipeline and regulatory changes affecting future projections.
FAQs
1. How does price sensitivity affect Vyondys 53's market?
Reimbursement challenges and payer negotiations influence net pricing, with price reductions likely as biosimilar or competing therapies emerge.
2. What is the impact of new exon-skipping drugs?
New therapies could capture market share, especially if they demonstrate superior efficacy or broader mutation coverage.
3. How do regulatory policies influence prices?
Orphan drug status provides market exclusivity, supporting high prices. Policy changes targeting drug affordability could lead to price reductions.
4. How might biosimilars affect the market?
Biosimilars could enter post-exclusivity in 2025, intensifying price competition and reducing revenue per patient.
5. What is the role of off-label use in revenue projections?
Off-label use remains limited due to mutation-specific efficacy, with primary revenues driven by approved indications and diagnosed patients.
References
- Food and Drug Administration. (2019). FDA approves Vyondys 53 to treat Duchenne muscular dystrophy. FDA.
- IQVIA. (2022). U.S. Prescription Drug Market Reports.
- Duchenne Foundation. (2022). Patient prevalence and mutation distribution.
- Wall Street Journal. (2022). Analysis of drug pricing trends.
- FDA. (2022). Exon skipping therapies market outlook.
